XML 159 R33.htm IDEA: XBRL DOCUMENT
v3.19.3.a.u2

Revenues (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2019
Revenue from Contract with Customer [Abstract] |
Disaggregation of revenue by product and by geographic area | Revenues were as follows (in millions):
|  | Year ended December 31, 2019
|  | U.S. |  | ROW |  | Total
Enbrel® (etanercept) |  | $ | 5,050 |  |  | $ | 176 |  |  | $ | 5,226 |
Neulasta® (pegfilgrastim) |  | 2,814 |  |  | 407 |  |  | 3,221 |
Prolia® (denosumab) |  | 1,772 |  |  | 900 |  |  | 2,672 |
XGEVA® (denosumab) |  | 1,457 |  |  | 478 |  |  | 1,935 |
Aranesp® (darbepoetin alfa) |  | 758 |  |  | 971 |  |  | 1,729 |
KYPROLIS® (carfilzomib) |  | 654 |  |  | 390 |  |  | 1,044 |
EPOGEN® (epoetin alfa) |  | 867 |  |  | — |  |  | 867 |
Sensipar®/Mimpara® (cinacalcet) |  | 252 |  |  | 299 |  |  | 551 |
Other products |  | 2,907 |  |  | 2,052 |  |  | 4,959 |
Total product sales(1) |  | 16,531 |  |  | 5,673 |  |  | 22,204 |
Other revenues |  | 693 |  |  | 465 |  |  | 1,158 |
Total revenues |  | $ | 17,224 |  |  | $ | 6,138 |  |  | $ | 23,362 |
|  | Year ended December 31, 2018
|  | U.S. |  | ROW |  | Total
ENBREL |  | $ | 4,807 |  |  | $ | 207 |  |  | $ | 5,014 |
Neulasta® |  | 3,866 |  |  | 609 |  |  | 4,475 |
Prolia® |  | 1,500 |  |  | 791 |  |  | 2,291 |
Aranesp® |  | 942 |  |  | 935 |  |  | 1,877 |
XGEVA® |  | 1,338 |  |  | 448 |  |  | 1,786 |
Sensipar®/Mimpara® |  | 1,436 |  |  | 338 |  |  | 1,774 |
EPOGEN® |  | 1,010 |  |  | — |  |  | 1,010 |
KYPROLIS® |  | 583 |  |  | 385 |  |  | 968 |
Other products |  | 1,947 |  |  | 1,391 |  |  | 3,338 |
Total product sales(1) |  | 17,429 |  |  | 5,104 |  |  | 22,533 |
Other revenues |  | 929 |  |  | 285 |  |  | 1,214 |
Total revenues |  | $ | 18,358 |  |  | $ | 5,389 |  |  | $ | 23,747 |
|  | Year ended December 31, 2017
|  | U.S. |  | ROW |  | Total
ENBREL |  | $ | 5,206 |  |  | $ | 227 |  |  | $ | 5,433 |
Neulasta® |  | 3,931 |  |  | 603 |  |  | 4,534 |
Aranesp® |  | 1,114 |  |  | 939 |  |  | 2,053 |
Prolia® |  | 1,272 |  |  | 696 |  |  | 1,968 |
Sensipar®/Mimpara® |  | 1,374 |  |  | 344 |  |  | 1,718 |
XGEVA® |  | 1,157 |  |  | 418 |  |  | 1,575 |
EPOGEN® |  | 1,096 |  |  | — |  |  | 1,096 |
KYPROLIS® |  | 562 |  |  | 273 |  |  | 835 |
Other products |  | 1,419 |  |  | 1,164 |  |  | 2,583 |
Total product sales(1) |  | 17,131 |  |  | 4,664 |  |  | 21,795 |
Other revenues |  | 898 |  |  | 156 |  |  | 1,054 |
Total revenues |  | $ | 18,029 |  |  | $ | 4,820 |  |  | $ | 22,849 |
____________ (1) Hedging gains and losses, which are included in product sales, were not material for the years ended December 31, 2019, 2018 and 2017.
Revenues earned from major customers | Certain information with respect to these customers was as follows (dollar amounts in millions):
| Years ended December 31,
| 2019 |  | 2018 |  | 2017
AmerisourceBergen Corporation: |  |  |  |  |
Gross product sales | $ | 12,301 |  |  | $ | 12,091 |  |  | $ | 10,742 |
% of total gross revenues | 33 | % |  | 33 | % |  | 31 | %
McKesson Corporation: |  |  |  |  |
Gross product sales | $ | 11,795 |  |  | $ | 11,434 |  |  | 10,625 |
% of total gross revenues | 31 | % |  | 31 | % |  | 30 | %
Cardinal Health, Inc.: |  |  |  |  |
Gross product sales | $ | 6,538 |  |  | $ | 7,475 |  |  | $ | 7,049 |
% of total gross revenues | 17 | % |  | 20 | % |  | 20 | %

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -URI http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=118260190&loc=d3e13531-108611 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 16 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 21 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592 + Details
Name: | us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration